Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR

Journal of Pharmacology and Experimental Therapeutics

Volumn 282, Issue 3, 1997, Pages 1496-1502

  Bramson, H Neal ^a   Hermann, David ^a   Batchelor, Kenneth W ^a   Lee, Frank W ^a   James, Michael K ^b   Frye, Stephen V ^a  

^a GLAXOSMITHKLINE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17BETA (N,N DIETHYLCARBAMOYL) 4 METHYL 4 AZA 5ALPHA ANDROSTAN 3 ONE; ANDROGEN RECEPTOR; ANDROSTANOLONE; DUTASTERIDE; FINASTERIDE; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOG; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; ENZYME INHIBITION; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RAT; TESTOSTERONE BLOOD LEVEL;

ANIMALS; AZASTEROIDS; CHOLESTENONE 5 ALPHA-REDUCTASE; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FINASTERIDE; HALF-LIFE; HUMANS; MALE; OXIDOREDUCTASES; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR;

EID: 0030886845     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. BOXENBAUM, H.: Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J. Pharmacol. Biopharm. 10: 201-227, 1982.
2. BROOKS, J. R., BERMAN, D., GLITZER, M. S., GORDON, L. R., PRIMKA, R. L., REYNOLDS, G. F. AND RASMUSSON, G. H.: Effect of a new 5-alpha reductase inhibitor on size, histologic characteristics and androgen concentrations of the canine prostate. Prostate 3: 35-44, 1982.
3. BULL, H. G., GARCIA-CALVO, M., ANDERSSON, S., BAGINSKY, W. F., CHAN, H. K., ELLSWORTH, D. E., MILLER, R. M., STEARNS, R. A., BAKSHI, R. K., RASMUSSON, G. H., TOLMAN, R. L., MYERS, R. W., KOZARICH, J. W. AND HARRIS, G. S.: Mechanism-based inhibition of human steroid 5α-reductase by finasteride: Enzyme-catalyzed formation of NADP-dihydrofinasteride, a potent bisubstrate analog inhibitor. J. Am. Chem. Soc. 118: 2359-2365, 1996.
4. 14C]-finasteride after oral administration in humans. Drug Metab. Dispos. 20: 148-155, 1992.
5. DESCHEPPER, P. J., IMPERATO-MCGINLEY, J. AND VAN HECKEN, A.: Hormonal effects, tolerability, and preliminary kinetics in men of MK-906, a 5α-reductase inhibitor. Steroids 56: 469-471, 1991.
6. FALLER, B., FARLEY, D. AND NICK, H.: Finasteride: A slow-binding 5α-reductase inhibitor. Biochemistry 32: 5705-5710, 1993.
7. FRYE, S. V., HAFFNER, C. D., MALONEY, P. R., MOOK JR., R. A., DORSEY JR., G. F., HINER, R. N., BATCHELOR, K. W., BRAMSON, H. N., STUART, J. D., SCHWEIKER, S. L., VAN ARNOLD, J., BICKETT, D. M., MOSS, M. L., TIAN, G., UNWALLA, R. J., LEE, F. W., TIPPEN, T. K., JAMES, M. K., GRIZZLE, M. K., LONG, J. E. AND SCHUSTER, S. V.: 6-Azasteroids: Potent dual inhibitors of human type 1 and 2 steroid 5α-reductase. J. Med. Chem. 36: 4313-4315, 1993.
8. 5-steroid isomerase. J. Med. Chem. 37: 2352-2360, 1994.
9. 5-steroid isomerase by 6-azaandrost-4-en-3-ones: Optimization of the C17 substituent. J. Med. Chem. 38: 2621-2627, 1995.
10. GELLER, J.: Benign prostatic hyperplasia: Pathogenesis and medical therapy. J. Am. Geriat. Soc. 39: 1208-1216, 1991.
11. INGS, R. M. J.: Interspecies scaling and comparisons in drug development and toxicokinetics. Xenobiotica 20: 1201-1231, 1990.
12. KLEINBAUM, D. G., KUPPER, L. L. AND MULLER, K. E.: Applied Regression Analysis and Other Multivariate Methods, 2nd ed., p. 32, PWS-Kent, Boston, 1988.
13. LANGE, P. H.: Is the prostate pill finally here? N. Engl. J. Med. 327: 1234-1236, 1992.
14. MOORE, E., BRACKEN, B., BREMNER, W., GELLER, J., IMPERATO-MCGINLEY, J., MCCONNELL, J., ROY, J., TENOVER, L., VAUGHAN, D., PAPPAS, F., COOK, T., GORMLEY, G. AND STONER, E.: Proscar: Five-year experience. Eur. Urol. 28: 304-309, 1995.
15. MORDENTI, J.: Man versus beast: Pharmacokinetic scaling in mammals. J. Pharm. Sci. 75: 1028-1040, 1986.
16. MORRIS, D. M., GROSSE, C. M. AND SELINGER, K. A.: Determination of GG745 in human serum by LC/APCI/MS (Abstract). The 6th International Symposium for Pharmaceutical and Biomedical Analysis, St. Louis, 1995.
17. OHTAWA, M., MORIKAWA, H. AND SHIMAZAKI, J.: Pharmacokinetics and biochemical efficacy after single and multiple oral administration of N-(2-methyl-2-propyl)-3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide, a new type of specific competitive inhibitor of testosterone 5α-reductase, in volunteers. Eur. J. Drug Metab. Pharmacokinet. 16: 15-21, 1991.
18. RASMUSSON, G. H., REYNOLDS, G. F., STEINBERG, N. G., WALTON, E., PATEL, G. F., LIANG, T., CASCIERI, M. A., CHEUNG, A. H., BROOKS, J. R. AND BERMAN, C. Azasteroids: Structure-activity relationships for inhibition of 5α-reductase and of androgen receptor binding. J. Med. Chem. 29: 2298-2315, 1986.
19. RITTMASTER, R. S.: Finasteride. N. Engl. J. Med. 330: 120-125, 1994.
20. RUSSELL, D. W. AND WILSON, J. D.: Steroid 5α-reductase: Two genes/two enzymes. Annu. Rev. Biochem. 63: 25-61, 1994.
21. THIGPEN, A. E., SILVER, R. I., GUILEYARDO, J. M., CASEY, M. L., MCCONNELL, J. D. AND RUSSELL, D. W.: Tissue distribution and ontogeny of steroid 5α-reductase isozyme expression. J. Clin. Invest. 92: 903-910, 1993.
22. TIAN, G., STUART, J. D., MOSS, M. L., DOMANICO, P. L., BRAMSON, H. N., PATEL, I. R., DADWELL, S. H., OVERTON, L. K., KOST, T. A., MOOK, JR., R. A., FRYE, S. V., BATCHELOR, K. W. AND WISEMAN, J. S.: 17β-(N-tert-Butylcarbamoyl)-4-aza-5α-androstan-1-en-3-one is an active site-directed slow time-dependent inhibitor of human steroid 5α-reductase 1. Biochemistry 33: 2291-2296, 1994.
23. 1-4-azasteroids: Towards perfection of rates of time-dependent inhibition by using ligand binding energies. Biochemistry 34: 13453-13459, 1995.
24. TIAN, G.: In vivo time-dependent inhibition of human steroid 5α-reductase by finasteride. J. Pharmaceut. Sci. 85: 106-111, 1996.
25. VERMEULEN, A., GIAGULLI, V. A., DE SCHEPPER, P., BUNTINX, A. AND STONER, E.: Hormonal effects of an orally active 4-azasteroid inhibitor of 5α-reductase in humans. Prostate 14: 45-53, 1989.